Neuroimmunological blood brain barrier opening in experimental cerebral malaria

Adela Nacer1, Alexandru Movila, Kerstin Baer

  • 1Division of Medical Parasitology, Department of Microbiology, New York University School of Medicine, New York, New York, United States of America.

Plos Pathogens
|November 8, 2012
PubMed

Insights

Mouse models reveal that experimental cerebral malaria (ECM) involves regulated opening of the blood-brain barrier (BBB), leading to neurological signs and death. Therapies targeting this opening may improve outcomes.

Area of Science:

  • Immunology
  • Neuroscience
  • Parasitology

Background:

  • Plasmodium falciparum malaria causes nearly one million deaths annually.
  • Understanding cerebral malaria pathogenesis is crucial due to difficulties in human studies.
  • Mouse models are essential for studying experimental cerebral malaria (ECM).

Purpose of the Study:

  • To compare the effects of different Plasmodium species on blood-brain barrier (BBB) integrity and brain histopathology in various mouse models.
  • To elucidate the mechanisms underlying disease progression in experimental cerebral malaria (ECM).

Main Methods:

  • Infection of CBA/CaJ, Swiss Webster, Balb/c, and A/J mice with Plasmodium berghei ANKA, P. berghei NK65, P. yoelii 17XL, and P. yoelii YM.
  • Assessment of neurological signs, cerebral hemorrhages, and BBB dysfunction.
  • Intravital imaging to visualize infected erythrocytes and vascular events in postcapillary venules.
  • Evaluation of therapeutic interventions targeting LFA-1 mediated interactions and endothelial barrier function.

Main Results:

  • P. berghei ANKA induced ECM in susceptible mouse strains, characterized by neurological signs and BBB dysfunction.
  • P. berghei NK65 unexpectedly induced ECM in CBA/CaJ mice.
  • P. yoelii 17XL and P. yoelii YM caused lethal hyperparasitemia without ECM.
  • ECM involves platelet marginalization, fibrin deposition, CD14 expression, and vascular leakage in postcapillary venules.
  • LFA-1 blockade, imatinib, and FTY720 ameliorated ECM symptoms and prolonged survival.

Conclusions:

  • Neurological signs and coma in ECM result from regulated opening of paracellular and transcellular pathways at the neuroimmunological BBB.
  • Targeting leukocyte adhesion and endothelial barrier dysfunction offers potential therapeutic strategies for cerebral malaria.